Linked Life Data

14612551

Source:http://linkedlifedata.com/resource/pubmed/id/14612551

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14612551rdf:typepubmed:Citationlld:pubmed
pubmed-article:14612551lifeskim:mentionsumls-concept:C0017296lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C0600521lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C1518321lld:lifeskim
pubmed-article:14612551lifeskim:mentionsumls-concept:C0450363lld:lifeskim
pubmed-article:14612551pubmed:issue21lld:pubmed
pubmed-article:14612551pubmed:dateCreated2003-11-12lld:pubmed
pubmed-article:14612551pubmed:abstractTextThe primary study objective was to determine the safety of intraprostatic administration of a replication-competent, oncolytic adenovirus containing a cytosine deaminase (CD)/herpes simplex virus thymidine kinase (HSV-1 TK) fusion gene concomitant with increasing durations of 5-fluorocytosine and valganciclovir prodrug therapy and conventional-dose three-dimensional conformal radiation therapy (3D-CRT) in patients with newly diagnosed, intermediate- to high-risk prostate cancer. Secondary objectives were to determine the persistence of therapeutic transgene expression in the prostate and to examine early posttreatment response. Fifteen patients in five cohorts received a single intraprostatic injection of 10(12) viral particles of the replication-competent Ad5-CD/TKrep adenovirus on day 1. Two days later, patients were administered 5-fluorocytosine and valganciclovir prodrug therapy for 1 (cohorts 1-3), 2 (cohort 4), or 3 (cohort 5) weeks along with 70-74 Gy 3D-CRT. Sextant needle biopsy of the prostate was obtained at 2 (cohort 1), 3 (cohort 2), and 4 (cohort 3) weeks for determination of the persistence of transgene expression. There were no dose-limiting toxicities and no significant treatment-related adverse events. Ninety-four percent of the adverse events observed were mild to moderate and self-limiting. Acute urinary and gastrointestinal toxicities were similar to those expected for conventional-dose 3D-CRT. Therapeutic transgene expression was found to persist in the prostate for up to 3 weeks after the adenovirus injection. As expected for patients receiving definitive radiation therapy, all patients experienced significant declines in prostate-specific antigen (PSA). The mean PSA half-life in patients administered more than 1 week of prodrug therapy was significantly shorter than that of patients receiving prodrugs for only 1 week (0.6 versus 2.0 months; P < 0.02) and markedly shorter than that reported previously for patients treated with conventional-dose 3D-CRT alone (2.4 months). With a median follow-up of only 9 months, 5 of 10 (50%) patients not treated with androgen-deprivation therapy achieved a serum PSA < or = 0.5 ng/ml. The results demonstrate that replication-competent adenovirus-mediated double-suicide gene therapy can be combined safely with conventional-dose 3D-CRT in patients with intermediate- to high-risk prostate cancer. The shorter than expected PSA half-life in patients receiving more than 1 week of prodrug therapy may suggest a possible interaction between the oncolytic adenovirus and/or double-suicide gene therapies and radiation therapy.lld:pubmed
pubmed-article:14612551pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:languageenglld:pubmed
pubmed-article:14612551pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:citationSubsetIMlld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14612551pubmed:statusMEDLINElld:pubmed
pubmed-article:14612551pubmed:monthNovlld:pubmed
pubmed-article:14612551pubmed:issn0008-5472lld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:PeckL SLSlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:JueBBlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:KimJae HoJHlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:StrickerHansHlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:XiaXueqingXlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:FreytagSvend...lld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:PeabodyJamesJlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:DePeralta-Ven...lld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:PaielliDellDlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:BrownSteveSlld:pubmed
pubmed-article:14612551pubmed:authorpubmed-author:PradhanDeepak...lld:pubmed
pubmed-article:14612551pubmed:issnTypePrintlld:pubmed
pubmed-article:14612551pubmed:day1lld:pubmed
pubmed-article:14612551pubmed:volume63lld:pubmed
pubmed-article:14612551pubmed:ownerNLMlld:pubmed
pubmed-article:14612551pubmed:authorsCompleteYlld:pubmed
pubmed-article:14612551pubmed:pagination7497-506lld:pubmed
pubmed-article:14612551pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:meshHeadingpubmed-meshheading:14612551...lld:pubmed
pubmed-article:14612551pubmed:year2003lld:pubmed
pubmed-article:14612551pubmed:articleTitlePhase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.lld:pubmed
pubmed-article:14612551pubmed:affiliationDepartment of Radiation Oncology, Henry Ford Health System, One Ford Place, Detroit, Michigan 48202, USA. sfreyta1@hfhs.orglld:pubmed
pubmed-article:14612551pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14612551pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:14612551pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14612551pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:14612551pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14612551lld:pubmed